Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus

Executive Summary

Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.

You may also be interested in...



COVID-19 Vaccine Access Uproar Underscores Importance Of At-Risk Manufacturing

Sanofi CEO Hudson tries to reassure France on access, but notes that Europe does not currently have a program to assure a supply of a coronavirus vaccine as soon as safety and efficacy have been established.

A Downside Of Pandemic Preparedness: Wall Street May Not Value Government Contracts

Human Genome Sciences founder William Haseltine says company's stock did not move following BARDA contract for its anthrax treatment; advises industry to forget about IP for COVID-19 products.

BARDA Shake Up May Prompt Broad Review Of Politicization of Countermeasures Office

Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS141704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel